Free Trial

HCW Biologics (HCWB) Competitors

HCW Biologics logo
$4.50 +0.28 (+6.64%)
Closing price 10/14/2025 04:00 PM Eastern
Extended Trading
$4.50 0.00 (0.00%)
As of 10/14/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCWB vs. SONN, PYRGF, AKTX, TENX, IMA, SCYX, QTTB, DARE, PMN, and KZR

Should you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include Sonnet BioTherapeutics (SONN), PyroGenesis Canada (PYRGF), Akari Therapeutics (AKTX), Tenax Therapeutics (TENX), ImageneBio (IMA), SCYNEXIS (SCYX), Q32 Bio (QTTB), Dare Bioscience (DARE), Promis Neurosciences (PMN), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry.

HCW Biologics vs. Its Competitors

Sonnet BioTherapeutics (NASDAQ:SONN) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 8.5% of Sonnet BioTherapeutics shares are owned by company insiders. Comparatively, 42.7% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sonnet BioTherapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -1,368.55%. HCW Biologics' return on equity of 0.00% beat Sonnet BioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sonnet BioTherapeuticsN/A -4,646.10% -342.21%
HCW Biologics -1,368.55%N/A -40.72%

Sonnet BioTherapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 364.04%. HCW Biologics has a consensus price target of $35.00, suggesting a potential upside of 677.78%. Given HCW Biologics' higher possible upside, analysts plainly believe HCW Biologics is more favorable than Sonnet BioTherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonnet BioTherapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
HCW Biologics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Sonnet BioTherapeutics has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Sonnet BioTherapeutics has higher earnings, but lower revenue than HCW Biologics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonnet BioTherapeutics$20K1,471.87-$7.44MN/AN/A
HCW Biologics$832.84K11.63-$30.02M-$14.04-0.32

In the previous week, HCW Biologics had 1 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 4 mentions for HCW Biologics and 3 mentions for Sonnet BioTherapeutics. HCW Biologics' average media sentiment score of 0.66 beat Sonnet BioTherapeutics' score of 0.63 indicating that HCW Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sonnet BioTherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
HCW Biologics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

HCW Biologics beats Sonnet BioTherapeutics on 7 of the 12 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCWB vs. The Competition

MetricHCW BiologicsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.08M$3.36B$6.05B$10.52B
Dividend YieldN/A2.31%5.73%4.79%
P/E Ratio-0.3221.9085.0527.24
Price / Sales11.63476.87595.29234.24
Price / CashN/A46.9537.5761.53
Price / Book-0.7410.4312.676.74
Net Income-$30.02M-$52.58M$3.32B$276.59M
7 Day Performance-7.79%-1.55%-1.34%-0.47%
1 Month Performance-8.16%12.96%8.11%7.47%
1 Year Performance-79.91%15.43%78.90%34.58%

HCW Biologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCWB
HCW Biologics
1.6451 of 5 stars
$4.50
+6.6%
$35.00
+677.8%
-78.7%$9.08M$832.84K-0.3240
SONN
Sonnet BioTherapeutics
2.1328 of 5 stars
$5.05
-7.2%
$20.00
+296.0%
-6.9%$34.48M$1M0.0010
PYRGF
PyroGenesis Canada
0.0698 of 5 stars
$0.18
-2.0%
N/A-68.1%$34.36M$9.14M-3.0590High Trading Volume
AKTX
Akari Therapeutics
2.8254 of 5 stars
$1.05
+2.4%
$3.30
+214.3%
-63.0%$34.25MN/A0.009
TENX
Tenax Therapeutics
2.6271 of 5 stars
$7.49
-2.2%
$18.00
+140.3%
+98.2%$34.15MN/A-8.149Analyst Forecast
IMA
ImageneBio
3.3474 of 5 stars
$8.34
-3.1%
$35.50
+325.7%
-63.0%$33.44M$9.16M-1.0970Positive News
SCYX
SCYNEXIS
0.8395 of 5 stars
$0.79
+0.5%
N/A-46.9%$33.23M$3.75M-1.9860Analyst Forecast
QTTB
Q32 Bio
2.9611 of 5 stars
$2.52
+16.1%
$12.17
+382.8%
-91.6%$30.74MN/A-0.5939Analyst Forecast
High Trading Volume
DARE
Dare Bioscience
1.8459 of 5 stars
$2.24
-0.4%
$10.00
+346.4%
-41.6%$30.20M$10K-1.0530Positive News
PMN
Promis Neurosciences
3.4727 of 5 stars
$0.54
-1.4%
$4.33
+701.0%
-54.1%$29.11MN/A-2.585Analyst Downgrade
KZR
Kezar Life Sciences
3.7962 of 5 stars
$3.86
-1.8%
$9.00
+133.2%
-50.2%$28.27MN/A-0.4060High Trading Volume

Related Companies and Tools


This page (NASDAQ:HCWB) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners